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43.6 Gy. The estimated TD50 & γ50 for RT Only group were 64.2 Gy & 
1.58 when all the patients were included and those for subset of 
patients without post-RT COM were 67 Gy & 1.65. Those for 
Chemo+RT group were 59.7 Gy & 1.47 when all patients included and 
those for subset of patients without post-RT COM were 59.9 Gy & 
2.02. 
Conclusions: Post RT COM is statistically significant for incidence of 
SNHL. The decrease in TD5 and TD10 for post-RT SNHL in the dataset 
that included patients with post-RT COM suggest that occurrence of 
post-RT COM may decrease the dose for onset of post-RT SNHL. The 
analysis suggest that subset of patients with post-RT COM may be a 
high risk group for post-RT SNHL. 
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Purpose/Objective: As most patients survive early-stage prostate 
cancer after treatment, quality of life outcome has emerged as an 
important factor to consider in treatment decisions. Radiation-
induced genitourinary (GU) symptoms may impair patients' quality of 
life and still occur with a 5-year actuarial risk of 20%. Moreover, the 
incidence does not seem to plateau and may be expected many years 
after treatment. Therefore, the purpose of this study was to construct 
multi-component models for the prediction of late GU sequellae in 
prostate cancer patients. 
Materials and Methods: Data were available for 265 prostate cancer 
patients treated with primary or post-operative intensity-modulated 
radiation therapy. The median follow-up was 4 years (0.5-13 years). 
Toxicity was scored using an in-house developed toxicity scale. For 
model building, clinical data (age, smoking, diabetes,hypertension, 
pre-treatment symptoms, transurethral resection of the prostate 
(TUR)), treatment data (lymph node dissection, androgen deprivation, 
radical prostatectomy), dosimetric parameters (doses delivered to to 
the clinical target volume (CTV) and the bladder (B)) and 343 genetic 
polymorphisms were considered. Selection of parameters for the 
predicting model was achieved by lasso logistic regression followed by 
classic logistic regression for unbiased estimation of the coefficients. 
Missing data were handled by a stochastic expectation-maximisation 
(EM) algorithm. Performance of the model was expressed as the area 
under the curve (AUC) of the receiver operating characteristic (ROC) 
curve and as the false-negative rate (FNR) and false-positive rate 
(FPR) in the optimal point on the ROC curve. 
Results: In our series, grade ≥ 2 nocturia and hematuria are the most 
prevalent GU symptoms and encompass more than 50% of the grade ≥ 
2 symptoms presented. Late nocturia occurred in 29 of the 265 
patients (11%). The final prediction model has an AUC of 0.81 and 
contains the minimal CTV dose, the CTV volume, the volume of the 
bladder receiving at least 65 Gy, the presence of acute grade 2 
nocturia symptoms and polymorphisms rs1799983 (NOS3), rs104585 
(CASP8), rs4808611 (NR2F6) and rs6163 (CYP17A1). The FNR and FPR 
are, respectively, 17% and 27%. A total of 14% of the patients (n=36) 
developed late radiation-induced hematuria. The prediction model for 
late hematuria has an AUC of 0.79 and consists of seven parameters: 
the volume of the bladder receiving at least 75 Gy, age at last follow-
up visit, prior TUR and rs3931914 (HMGRC), rs2293054 (NOS1), 
rs708598 (PTGER2) and rs845552 (EGFR). The FNR and FPR are 28% and 
29%, respectively. 
Conclusions: Combining clinical, treatment, dosimetric and genetic 
factors has the potential to improve the prediction of late urinary 
toxicity. External validation of the prediction models is necessary 
before implementing these models in the clinic. 
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Purpose/Objective: Fas ligand (FASL, also known as APO-1L, CD95LG, 
CD178, TNFSF6) triggers the apoptotic cell-death by cross-linking with 
its receptor FAS (TNFSF6, CD95/APO-1), and after irradiation, 
expression of FAS and FASL is increased and has been associated with 
radiation-induced delayed cell death. In the present prospective 
study, we analyzed the role of common polymorphisms in the genes 
for FAS and FASL for the development of late toxicity after 
radiotherapy for prostate cancer.  
Materials and Methods: The association of FAS (-1377G>A, rs2234767 
and -670A>G, rs1800682) and FASL (-844C>T, rs763110) gene 
polymorphisms with high-grade late rectal and/or urinary toxicity 
(defined as late toxicity EORTC/RTOG grade≥2) was analyzed using 
607 prostate cancer patients treated with radiotherapy in curative 
intent. The selected polymorphisms were determined by 5´-nuclease 
(TaqMan) assays. 
Results: After a median follow-up time of 81 months, high-grade late 
rectal and/or urinary toxicity was observed in 175 patients (29.7%). In 
Kaplan-Meier analysis, the -844C>T polymorphism was significantly 
associated with high-grade late toxicity (p=0.007). In univariate Cox 
proportional hazard analysis, carriers of the -844C>T polymorphism 
were at decreased risk of high-grade late toxicity (HR=0.686, 95%CI 
0.541 - 0.87; p=0.002). In multivariate Cox regression analysis 
including clinical and dosimetric parameters as potential confounders, 
the -844C>T polymorphism in the FASL gene remained a predictive 
factor (HR=0.642, 95%CI 0.459 - 0.896; p=0.009). For the remaining 
analyzed polymorphisms no significant associations were found. 
Conclusions: We conclude that the FASL -844C>T polymorphism may 
be protective against the development of high-grade late toxicity 
after radiotherapy for prostate cancer.  
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Purpose/Objective: Acute mucositis is a serious dose-limiting side 
effect during and immediately after primary RT, concurrent 
chemoradiation (ChemoRT) or a combination of cetuximab and 
accelerated RT (bioradiation or BioRT) resulting in compromised oral 
intake due to pain and dysphagia. The purpose of this study was to 
identify pre treatment variables and DVH parameters that might 
predict acute mucositis grade 2-4 at the end of the treatment. 
Materials and Methods: This prospective study included 170 patients 
with head and neck squamous cell carcinoma (HNSSC) included in a 
standardized follow up program (SFP). Patients were treated with 
curative intent. Acute mucositis was assessed at baseline and at 
consecutive time points during (weekly) and after treatment. Acute 
mucositis was defined as grade 2-4 according the RTOG grading 
system. In all cases the oral cavity as well as parotid glands, 
submandibular glands, spinal cord and swallowing organs at risk were 
delineated on the planning CT scans. Dose volume histogram (DVH) 
parameters were collected as well as pre treatment variables. The 
predictive model was designed using a multiple logistic regression 
analysis. The primary endpoint was acute mucositis grade 2-4 assessed 
in the last week of the treatment. 
Results: The predictive model consisted of the pre treatment 
variables: concurrent chemoradiation (coefficient=1.93) and 
bioradiation (coefficient=1.33). The V60 (the volume of the oral cavity 
receiving ≤ 60 Gy) was the single statistically significant DVH 
parameter (coefficient=0.06) and was included in the model. The 
model performance was good expressed by the area under the curve 
(AUC = 0.83 (p=0.000)) and the Hosmer Lemeshow goodness-of-fit test 
(p=0.79). 
Conclusions: The severity of acute mucositis in the last week of 
primary RT, ChemoRT or BioRT in head and neck cancer patients can 
be predicted by two pre treatment variables and one DVH parameter 
(V60). The use of V60 can be helpful in IMRT optimization to reduce this 
side effect or select high-risk patients for intensified supportive care.  
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Purpose/Objective: To investigate if post-radiotherapy (RT) 
scintigraphy measurements of salivary glands manifest such 
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differences among the patients that could be explained by individual 
radiosensitivity. 
Materials and Methods: The salivary gland ejection (excretion) 
fraction (sEF) was measured by Tc-99m pertechnetate scintigraphy for 
50 patients receiving IMRT for head and neck cancer. The scintigraphy 
was performed before RT and repeated 6 and 12 months after RT. 
Only the glands with Dmean values between 15 Gy and 45 Gy were 
included and the glands which were not functioning properly prior to 
RT were excluded. The relative ejection fraction rEF(t) = sEF(t) / 
sEF(0) was first compared for both parotid glands of the same patient 
at the same time of measurement. Next, the rEF values at 6 and 12 
months after RT were compared for the same gland. To enable the 
comparison of rEF values between glands receiving varying Dmean, the 
mean effect of the absorbed dose on the gland was eliminated. This 
was achieved by dividing the rEF value for the gland with the 
respective value of sigmoidal mean dose response curve for the whole 
group of patients (rEF0=rEF(t)*(1+(Dmean/D50)^k)). Fisher’s exact test 
was used in the analysis with two categories defined by median rEF0. 
Average errors in Dmean values for the glands due to patient positioning 
errors were corrected based on portal images. 
Results: The values for rEF0 ranged from 0 to 2.7. A significant 
association between rEF0 for left and right parotid glands was found 
(χ2=6.0, p<0.025). Some patients show systematically lower or higher 
rEF0 than the median for both parotid glands. This could be explained 
by three possible reasons, as the effect of positioning errors to Dmean 
was excluded: 1) the variations result from the measurement 
technique or 2) the patients react differently to the lemon juice 
stimulus given during the scintigraphy or 3) the post-RT sEF is affected 
by varying individual responses to radiation. The rEF0 values for the 
same gland at 6 and 12 months after RT gave a statistically significant 
relationship between the two variables (χ2=4.73, p≤0.05) (Table 1). 
The same patients had low or high values of rEF0 for both parotid 
glands at both times of measurement. As this behaviour is seen in both 
measurements, it can not be due to fluctuations caused by 
measurement technique. Also, we believe that by using relative values 
instead of single sEF values, we can at least partly overcome the 
problem of patients reacting differently to the stimulus, assuming that 
the factors, such as smoking, that may influence saliva production 
remain the same between the measurements. As a result of this 
indirect deduction, we conclude that the systematic variation in rEF0 
reflects individual differences in radiosensitivity. 
 
 
Conclusions: According to our interpretation the systematic variations 
seen in post-RT salivary gland scintigraphy measurements can be 
explained by individual differences in radiosensitivity. Quantitative 
extraction of individual radiosensitivity requires further studies.  
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Purpose/Objective: Ferrofluid particles being subjected to an 
electromagnetic field show remarkable heating effects related to 
losses during the magnetization process and Joule heating of the 
particles. The temperature enhancement which occurs in a magnetic 
ferrofluid system under the influence of an external high frequency 
magnetic field has found applications in breast tumor hyperthermia 
treatment therapy. The main objectives are the uniformity of the 
temperature distribution and the target value of temperature to be up 
to 42°C in the controlled region for magnetic hyperthermia 
treatment. This temperature control is hard to implement because of 
many tissue individual variations and other therapy conditions. 
Materials and Methods: For determination of the thermal field 
distribution in magnetic hyperthermia therapy, a coupled 
electromagnetic – thermal - fluid dynamics field computational model 
is developed. The electromagnetic field distribution inside the 
conductive tissue region depends on the time varying magnetic flux 
density. The heat sources are defined by the electric losses in tissue, 
acquired by the solution of the electromagnetic field problem. The 
computational model uses anatomically precise multilevel geometrical 
model of human breast with known electrical tissue properties, blood 
and liquor flow speeds in its vessels. Model contains information about 
real cancer structure sample acquired by surgical procedure. Cancer 
and normal electrical tissue properties are directly measured for this 
sample by precise measurement system. 
Results: Sample under treatment is in stage T2N2M1 with maximal 
size of 25 mm. Sample volume is 317 mm3. Ferrofluid solution is 
injected at cancer sample. Ferrofluid filled volume in sample is 24 
mm3. Thermal field distribution in cancer model is presented in Fig.1. 
Maximal temperature acquired is 42.3oC. Temperature maximum 
represents the position of ferrofluid volume. Results from this model 
are validated by infrared thermography measurements of the sample. 
Field values and distributions correspond well to these one acquired 
by the model. 
 Fig.1 Thermal field distribution in tumor model for time period of 
120s. 
 
Conclusions: The coupled electromagnetic-fluid dynamics-thermal 
field computational modeling is capable to predict the magnetic 
ferrofluid hyperthermia thermal effects on live tissue. The developed 
model can be used for therapy planning and also design and 
optimization of interaction between electromagnetic devices and 
biological structures.  
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Purpose/Objective: To study whether genetic single nucleotide 
polymorphisms (SNPs) are predictive of erectile dysfunction (ED) in 
prostate cancer patients treated with radiotherapy, we investigated 
the relationship between genotypes in SNP data and Expanded 
Prostate Cancer Index Composite (EPIC) scores. 
Materials and Methods: In our previous study, we examined SNPs 
obtained for 124 prostate cancer patients who received radiotherapy 
(RT) and, after identifying a statistically-managable number of SNPs 
using a novel system biology approach, we indentified a single SNP 
(rs2032809) that was statistically associated with post-RT adverse 
 
